RU2015144155A - Мускариновые агонисты - Google Patents
Мускариновые агонисты Download PDFInfo
- Publication number
- RU2015144155A RU2015144155A RU2015144155A RU2015144155A RU2015144155A RU 2015144155 A RU2015144155 A RU 2015144155A RU 2015144155 A RU2015144155 A RU 2015144155A RU 2015144155 A RU2015144155 A RU 2015144155A RU 2015144155 A RU2015144155 A RU 2015144155A
- Authority
- RU
- Russia
- Prior art keywords
- optionally substituted
- compound
- eye
- octan
- methylpropyl
- Prior art date
Links
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 210000001508 eye Anatomy 0.000 claims 19
- 201000010099 disease Diseases 0.000 claims 17
- 238000000034 method Methods 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 claims 9
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- -1 substituted Chemical class 0.000 claims 9
- 208000010412 Glaucoma Diseases 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 210000004087 cornea Anatomy 0.000 claims 7
- 206010023332 keratitis Diseases 0.000 claims 7
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 7
- 208000002780 macular degeneration Diseases 0.000 claims 7
- 206010012289 Dementia Diseases 0.000 claims 6
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 6
- 206010013774 Dry eye Diseases 0.000 claims 6
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 6
- 208000010217 blepharitis Diseases 0.000 claims 6
- 210000004175 meibomian gland Anatomy 0.000 claims 6
- 206010003645 Atopy Diseases 0.000 claims 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims 5
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 4
- 208000005100 Herpetic Keratitis Diseases 0.000 claims 4
- 206010022941 Iridocyclitis Diseases 0.000 claims 4
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims 4
- 206010030043 Ocular hypertension Diseases 0.000 claims 4
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims 4
- 206010061323 Optic neuropathy Diseases 0.000 claims 4
- 206010034277 Pemphigoid Diseases 0.000 claims 4
- 241001303601 Rosacea Species 0.000 claims 4
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 4
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 4
- 206010046851 Uveitis Diseases 0.000 claims 4
- 208000036142 Viral infection Diseases 0.000 claims 4
- 230000000172 allergic effect Effects 0.000 claims 4
- 125000005336 allyloxy group Chemical group 0.000 claims 4
- 201000004612 anterior uveitis Diseases 0.000 claims 4
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 4
- 208000010668 atopic eczema Diseases 0.000 claims 4
- 208000037976 chronic inflammation Diseases 0.000 claims 4
- 230000006020 chronic inflammation Effects 0.000 claims 4
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims 4
- 208000030533 eye disease Diseases 0.000 claims 4
- 208000027993 eye symptom Diseases 0.000 claims 4
- 201000010884 herpes simplex virus keratitis Diseases 0.000 claims 4
- 230000001771 impaired effect Effects 0.000 claims 4
- 230000004410 intraocular pressure Effects 0.000 claims 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims 4
- 208000020911 optic nerve disease Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 201000004700 rosacea Diseases 0.000 claims 4
- 230000035945 sensitivity Effects 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 3
- 206010003694 Atrophy Diseases 0.000 claims 3
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 3
- 206010011017 Corneal graft rejection Diseases 0.000 claims 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010029240 Neuritis Diseases 0.000 claims 3
- 208000003435 Optic Neuritis Diseases 0.000 claims 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 3
- 125000001118 alkylidene group Chemical group 0.000 claims 3
- 125000005133 alkynyloxy group Chemical group 0.000 claims 3
- 206010069664 atopic keratoconjunctivitis Diseases 0.000 claims 3
- 230000037444 atrophy Effects 0.000 claims 3
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 3
- 201000011190 diabetic macular edema Diseases 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 239000000472 muscarinic agonist Substances 0.000 claims 3
- 201000004768 pinguecula Diseases 0.000 claims 3
- 208000004644 retinal vein occlusion Diseases 0.000 claims 3
- 206010001488 Aggression Diseases 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 206010002650 Anorexia nervosa and bulimia Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 208000030814 Eating disease Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims 2
- 208000004547 Hallucinations Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010033864 Paranoia Diseases 0.000 claims 2
- 208000027099 Paranoid disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 241001621636 Pterygia Species 0.000 claims 2
- 201000002154 Pterygium Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 206010047571 Visual impairment Diseases 0.000 claims 2
- 230000007000 age related cognitive decline Effects 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 208000037765 diseases and disorders Diseases 0.000 claims 2
- 235000014632 disordered eating Nutrition 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 230000000324 neuroprotective effect Effects 0.000 claims 2
- 208000019906 panic disease Diseases 0.000 claims 2
- 208000019899 phobic disease Diseases 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000020685 sleep-wake disease Diseases 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000029257 vision disease Diseases 0.000 claims 2
- 230000004393 visual impairment Effects 0.000 claims 2
- ITRXTZZBZSFHJX-SJFWKDOISA-N C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=C(C1=CC=CC=C21)C)C Chemical compound C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=C(C1=CC=CC=C21)C)C ITRXTZZBZSFHJX-SJFWKDOISA-N 0.000 claims 1
- JRJZHTCPZCYIBW-LAQKFSSHSA-N C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC(=CC=C21)C)C Chemical compound C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC(=CC=C21)C)C JRJZHTCPZCYIBW-LAQKFSSHSA-N 0.000 claims 1
- XRUAMHUABWEBDK-FOZKEBTBSA-N C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=C(C=C21)C(F)(F)F)C Chemical compound C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=C(C=C21)C(F)(F)F)C XRUAMHUABWEBDK-FOZKEBTBSA-N 0.000 claims 1
- VMKXOJMOJZBXDN-LAQKFSSHSA-N C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=C(C=C21)C)C Chemical compound C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=C(C=C21)C)C VMKXOJMOJZBXDN-LAQKFSSHSA-N 0.000 claims 1
- JKEYKALOMMSCEY-FOZKEBTBSA-N C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=C(C=C21)F)C Chemical compound C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=C(C=C21)F)C JKEYKALOMMSCEY-FOZKEBTBSA-N 0.000 claims 1
- OHIAMUPUAFQXRN-UDNPVYIMSA-N C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=C(C=C21)OC)C Chemical compound C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=C(C=C21)OC)C OHIAMUPUAFQXRN-UDNPVYIMSA-N 0.000 claims 1
- SFDGDCVMPXBWNZ-ZYOXULSGSA-N C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=CC(=C21)C)C Chemical compound C1(CC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=CC(=C21)C)C SFDGDCVMPXBWNZ-ZYOXULSGSA-N 0.000 claims 1
- JDBGWWXCMUKFAZ-LAQKFSSHSA-N C1(CCC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=CC=C21)C Chemical compound C1(CCC1)COC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=CC=C21)C JDBGWWXCMUKFAZ-LAQKFSSHSA-N 0.000 claims 1
- YYECPNPFTGIKTR-NTSUVRSXSA-N COCCC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=C(C=C21)F)C Chemical compound COCCC1CC2CCC(C1)N2C[C@H](CN2N=CC1=CC=C(C=C21)F)C YYECPNPFTGIKTR-NTSUVRSXSA-N 0.000 claims 1
- 208000008069 Geographic Atrophy Diseases 0.000 claims 1
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 claims 1
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 claims 1
- 102000007216 Muscarinic M4 Receptor Human genes 0.000 claims 1
- 108010008414 Muscarinic M4 Receptor Proteins 0.000 claims 1
- 229940121743 Muscarinic receptor agonist Drugs 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 claims 1
- 210000003372 endocrine gland Anatomy 0.000 claims 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361790364P | 2013-03-15 | 2013-03-15 | |
| US61/790,364 | 2013-03-15 | ||
| PCT/US2014/026998 WO2014152144A1 (en) | 2013-03-15 | 2014-03-14 | Muscarinic agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015144155A true RU2015144155A (ru) | 2017-04-24 |
Family
ID=50439523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015144155A RU2015144155A (ru) | 2013-03-15 | 2014-03-14 | Мускариновые агонисты |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9670209B2 (enExample) |
| EP (1) | EP2976079A1 (enExample) |
| JP (1) | JP2016513677A (enExample) |
| KR (1) | KR20150143439A (enExample) |
| CN (1) | CN105120865A (enExample) |
| AU (1) | AU2014240139A1 (enExample) |
| BR (1) | BR112015021271A2 (enExample) |
| CA (1) | CA2903276A1 (enExample) |
| IL (1) | IL241001A0 (enExample) |
| MX (1) | MX2015012043A (enExample) |
| RU (1) | RU2015144155A (enExample) |
| TW (1) | TW201446761A (enExample) |
| WO (1) | WO2014152144A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2015144155A (ru) | 2013-03-15 | 2017-04-24 | Акадиа Фармасьютикалз Инк. | Мускариновые агонисты |
| KR101613245B1 (ko) | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| EP3436434B1 (en) | 2016-03-31 | 2020-07-08 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5707798A (en) | 1993-07-13 | 1998-01-13 | Novo Nordisk A/S | Identification of ligands by selective amplification of cells transfected with receptors |
| JPH10152470A (ja) * | 1996-09-25 | 1998-06-09 | Yoshitomi Pharmaceut Ind Ltd | ピペラジン化合物 |
| EP1535912A1 (en) | 2000-04-28 | 2005-06-01 | Arcadia Pharmaceuticals Inc. | Muscarinic agonists |
| ES2238437T3 (es) | 2000-04-28 | 2005-09-01 | Acadia Pharmaceuticals Inc. | Agonistas muscarinicos. |
| US7550459B2 (en) * | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| CA2520125A1 (en) * | 2003-03-28 | 2004-10-14 | Acadia Pharmaceuticals Inc. | Muscarinic m1 receptor agonists for pain management |
| US7931909B2 (en) | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| RU2015144155A (ru) | 2013-03-15 | 2017-04-24 | Акадиа Фармасьютикалз Инк. | Мускариновые агонисты |
-
2014
- 2014-03-14 RU RU2015144155A patent/RU2015144155A/ru not_active Application Discontinuation
- 2014-03-14 AU AU2014240139A patent/AU2014240139A1/en not_active Abandoned
- 2014-03-14 WO PCT/US2014/026998 patent/WO2014152144A1/en not_active Ceased
- 2014-03-14 JP JP2016502306A patent/JP2016513677A/ja active Pending
- 2014-03-14 US US14/774,685 patent/US9670209B2/en not_active Expired - Fee Related
- 2014-03-14 MX MX2015012043A patent/MX2015012043A/es unknown
- 2014-03-14 CN CN201480015640.8A patent/CN105120865A/zh active Pending
- 2014-03-14 KR KR1020157025205A patent/KR20150143439A/ko not_active Withdrawn
- 2014-03-14 CA CA2903276A patent/CA2903276A1/en not_active Abandoned
- 2014-03-14 TW TW103109294A patent/TW201446761A/zh unknown
- 2014-03-14 BR BR112015021271A patent/BR112015021271A2/pt not_active IP Right Cessation
- 2014-03-14 EP EP14715518.8A patent/EP2976079A1/en not_active Withdrawn
-
2015
- 2015-09-01 IL IL241001A patent/IL241001A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016513677A (ja) | 2016-05-16 |
| US9670209B2 (en) | 2017-06-06 |
| EP2976079A1 (en) | 2016-01-27 |
| AU2014240139A1 (en) | 2015-09-17 |
| US20160039819A1 (en) | 2016-02-11 |
| CN105120865A (zh) | 2015-12-02 |
| IL241001A0 (en) | 2015-11-30 |
| WO2014152144A1 (en) | 2014-09-25 |
| KR20150143439A (ko) | 2015-12-23 |
| CA2903276A1 (en) | 2014-09-25 |
| BR112015021271A2 (pt) | 2017-08-22 |
| TW201446761A (zh) | 2014-12-16 |
| MX2015012043A (es) | 2016-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102602947B1 (ko) | 제약 화합물 | |
| AU2019245390B2 (en) | Mono-(acid) salts of 6-aminoisoquinolines and uses thereof | |
| KR20140091022A (ko) | 벤젠술폰아미드 화합물 및 치료제로서의 그의 용도 | |
| JP6975515B2 (ja) | Ｔｒｐａ１モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物 | |
| KR20140105445A (ko) | 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도 | |
| TW201920197A (zh) | 化合物 | |
| JP2019536757A (ja) | 造血器型プロスタグランジンｄシンターゼ阻害剤としての１，３二置換シクロブタンまたはアゼチジン誘導体 | |
| JP2017525677A (ja) | 治療用化合物及びその使用方法 | |
| JP2018520107A (ja) | 置換ベンズアミド及びその使用方法 | |
| EP2804861A1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| RU2015144155A (ru) | Мускариновые агонисты | |
| AU2017347549A1 (en) | Therapeutic compounds and methods of use thereof | |
| PE20221020A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1 | |
| JP2016513677A5 (enExample) | ||
| JP2019521163A (ja) | 二環式プロリン化合物 | |
| JP2020535172A5 (enExample) | ||
| WO2021213353A1 (zh) | 酰胺或者磺酰胺类衍生物及其应用 | |
| CN115551846A (zh) | 1,4,5,6-四氢嘧啶-2-胺衍生物 | |
| JP2018535234A (ja) | ナトリウムチャネル遮断薬として有用な置換ベンズアミド | |
| EP3024825A1 (en) | Imidazolecarboxamides and their use as faah inhibitors | |
| JP2024514870A (ja) | ムスカリン作動薬が結合したα２アドレナリン作動薬コドラッグ | |
| JP6031719B2 (ja) | アルファ２アドレナリン作動性受容体のモジュレーターとしてのｎ−（イミダゾリジン−２−イリデン）キノリン誘導体 | |
| US9988350B2 (en) | Aniline derivative, pharmaceutical composition containing same, and use thereof | |
| WO2011040510A1 (ja) | インダゾール類縁体 | |
| WO2010041569A1 (ja) | インダゾール化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180529 |